Cargando…
Serum C-Reactive Protein and Interleukin-6 Levels as Biomarkers for Disease Severity and Clinical Outcomes in Patients with Idiopathic Granulomatous Mastitis
Idiopathic granulomatous mastitis (IGM) is a rare inflammatory breast disease mimicking breast cancer. Limited research has been conducted on the application of serum biomarkers. This study aims to investigate the association of serum biomarkers with disease severity in patients with IGM. From Novem...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8150275/ https://www.ncbi.nlm.nih.gov/pubmed/34066203 http://dx.doi.org/10.3390/jcm10102077 |
_version_ | 1783698112947159040 |
---|---|
author | Huang, Yi-Min Lo, Chiao Cheng, Chiao-Feng Lu, Cheng-Hsun Hsieh, Song-Chou Li, Ko-Jen |
author_facet | Huang, Yi-Min Lo, Chiao Cheng, Chiao-Feng Lu, Cheng-Hsun Hsieh, Song-Chou Li, Ko-Jen |
author_sort | Huang, Yi-Min |
collection | PubMed |
description | Idiopathic granulomatous mastitis (IGM) is a rare inflammatory breast disease mimicking breast cancer. Limited research has been conducted on the application of serum biomarkers. This study aims to investigate the association of serum biomarkers with disease severity in patients with IGM. From November 2011 to March 2020, medical records of patients with IGM were reviewed. Serum cytokine levels were measured in patients and healthy controls between July 2018 and March 2020. A total of 41 patients with histologically proven IGM were found. Serum interleukin (IL)-6 level was significantly higher in patients with IGM (n = 11) than healthy controls (n = 7). Serum IL-6 and C-reactive protein (CRP) levels were significantly higher in patients with severe disease than mild and moderate disease. Serum IL-6 (Spearman’s ρ = 0.855; p < 0.001) and CRP (Spearman’s ρ = 0.838; p = 0.001) levels were associated with time to resolution. A higher serum CRP level was associated with a longer time to resolution (B = 0.322; p < 0.001) in multiple linear regression analysis. Serum IL-6 and CRP levels can be used as biomarkers for the evaluation of disease severity in IGM. IL-6 may play a crucial role in the immunopathology of IGM. |
format | Online Article Text |
id | pubmed-8150275 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-81502752021-05-27 Serum C-Reactive Protein and Interleukin-6 Levels as Biomarkers for Disease Severity and Clinical Outcomes in Patients with Idiopathic Granulomatous Mastitis Huang, Yi-Min Lo, Chiao Cheng, Chiao-Feng Lu, Cheng-Hsun Hsieh, Song-Chou Li, Ko-Jen J Clin Med Article Idiopathic granulomatous mastitis (IGM) is a rare inflammatory breast disease mimicking breast cancer. Limited research has been conducted on the application of serum biomarkers. This study aims to investigate the association of serum biomarkers with disease severity in patients with IGM. From November 2011 to March 2020, medical records of patients with IGM were reviewed. Serum cytokine levels were measured in patients and healthy controls between July 2018 and March 2020. A total of 41 patients with histologically proven IGM were found. Serum interleukin (IL)-6 level was significantly higher in patients with IGM (n = 11) than healthy controls (n = 7). Serum IL-6 and C-reactive protein (CRP) levels were significantly higher in patients with severe disease than mild and moderate disease. Serum IL-6 (Spearman’s ρ = 0.855; p < 0.001) and CRP (Spearman’s ρ = 0.838; p = 0.001) levels were associated with time to resolution. A higher serum CRP level was associated with a longer time to resolution (B = 0.322; p < 0.001) in multiple linear regression analysis. Serum IL-6 and CRP levels can be used as biomarkers for the evaluation of disease severity in IGM. IL-6 may play a crucial role in the immunopathology of IGM. MDPI 2021-05-12 /pmc/articles/PMC8150275/ /pubmed/34066203 http://dx.doi.org/10.3390/jcm10102077 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Huang, Yi-Min Lo, Chiao Cheng, Chiao-Feng Lu, Cheng-Hsun Hsieh, Song-Chou Li, Ko-Jen Serum C-Reactive Protein and Interleukin-6 Levels as Biomarkers for Disease Severity and Clinical Outcomes in Patients with Idiopathic Granulomatous Mastitis |
title | Serum C-Reactive Protein and Interleukin-6 Levels as Biomarkers for Disease Severity and Clinical Outcomes in Patients with Idiopathic Granulomatous Mastitis |
title_full | Serum C-Reactive Protein and Interleukin-6 Levels as Biomarkers for Disease Severity and Clinical Outcomes in Patients with Idiopathic Granulomatous Mastitis |
title_fullStr | Serum C-Reactive Protein and Interleukin-6 Levels as Biomarkers for Disease Severity and Clinical Outcomes in Patients with Idiopathic Granulomatous Mastitis |
title_full_unstemmed | Serum C-Reactive Protein and Interleukin-6 Levels as Biomarkers for Disease Severity and Clinical Outcomes in Patients with Idiopathic Granulomatous Mastitis |
title_short | Serum C-Reactive Protein and Interleukin-6 Levels as Biomarkers for Disease Severity and Clinical Outcomes in Patients with Idiopathic Granulomatous Mastitis |
title_sort | serum c-reactive protein and interleukin-6 levels as biomarkers for disease severity and clinical outcomes in patients with idiopathic granulomatous mastitis |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8150275/ https://www.ncbi.nlm.nih.gov/pubmed/34066203 http://dx.doi.org/10.3390/jcm10102077 |
work_keys_str_mv | AT huangyimin serumcreactiveproteinandinterleukin6levelsasbiomarkersfordiseaseseverityandclinicaloutcomesinpatientswithidiopathicgranulomatousmastitis AT lochiao serumcreactiveproteinandinterleukin6levelsasbiomarkersfordiseaseseverityandclinicaloutcomesinpatientswithidiopathicgranulomatousmastitis AT chengchiaofeng serumcreactiveproteinandinterleukin6levelsasbiomarkersfordiseaseseverityandclinicaloutcomesinpatientswithidiopathicgranulomatousmastitis AT luchenghsun serumcreactiveproteinandinterleukin6levelsasbiomarkersfordiseaseseverityandclinicaloutcomesinpatientswithidiopathicgranulomatousmastitis AT hsiehsongchou serumcreactiveproteinandinterleukin6levelsasbiomarkersfordiseaseseverityandclinicaloutcomesinpatientswithidiopathicgranulomatousmastitis AT likojen serumcreactiveproteinandinterleukin6levelsasbiomarkersfordiseaseseverityandclinicaloutcomesinpatientswithidiopathicgranulomatousmastitis |